| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/16/2003 | US20030013641 Complexing drug with diketopiperazine; washing; separation of impurities |
| 01/16/2003 | US20030013179 Enzymatic polypeptide for use in the treatment of lysosomal storage disorders |
| 01/16/2003 | US20030013164 Generating linoleic acid derivatives; obtain chemical intermediates, incubate with lipase, recover fatty acid conjugated to linoleic acid |
| 01/16/2003 | US20030012830 Acetone, a salicylate-based compound and an emollient. |
| 01/16/2003 | US20030012826 Carotenoids; vitamins E, D, & C; thiamine; riboflavin; niacin; folic acid; pyridoxine; biotin; pantothenic acid; cobalamin; magnesium; manganese; zinc; selenium; chromium; copper; alpha lipoic acid; and lutein; added iron free |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012818 Bioactive molecule that is a non-glycosylated member of the cystine knot growth factor superfamily is physically entrapped in the polymeric matrix. |
| 01/16/2003 | US20030012817 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 01/16/2003 | US20030012816 Nitric oxide-producing hydrogel materials |
| 01/16/2003 | US20030012813 Cationic lipid with a lipophilic group derived from cholesterol; an amide or carbamate linker bond; an alkylene spacer arm; and a cationic primary, secondary, tertiary or quaternary amino group. facilitating nucleic acid transfer |
| 01/16/2003 | US20030012789 Conjugate of an antigen and a FcRn binding partner, wherein the antigen is characteristic of a tumor, and a pharmaceutically acceptable carrier |
| 01/16/2003 | US20030012785 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 01/16/2003 | US20030012784 Methods for treatment of inflammatory diseases |
| 01/16/2003 | US20030012779 Reducing the residual solvent content to a level effective to protect said preparation of monoclonal immunoglobulins from said radiation; optionally adding a stabilizer; and irradiating with a suitable radiation |
| 01/16/2003 | US20030012778 Reversibly inactivated acidified plasmin |
| 01/16/2003 | US20030012775 PEG conjugates of NK4 |
| 01/16/2003 | US20030012774 Mixture of gamma-cyclodextrin and coenzyme Q1O is treated by homogenisation and inputting energy. |
| 01/16/2003 | US20030012773 Diaper dermatitis preventative medication and a method for making and using same |
| 01/16/2003 | US20030012765 First polysaccharide crosslinked to second polysaccharide, selected from hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, heparan sulfate and alginate |
| 01/16/2003 | US20030012749 Applying a preparation comprising water, urea and a film-forming agent to remove and treat diseased nails affected by onychomycosis |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012738 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030012734 Biodegradable hydrogel having a visualization agent that reflects or emits light at a wavelength detectable to a human eyeast partially disposed within the interior. |
| 01/16/2003 | CA2452298A1 Lanolin substitute, production method thereof and applications of same |
| 01/16/2003 | CA2452257A1 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2451741A1 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | CA2451360A1 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | CA2451055A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | CA2433583A1 Composition of insulin for nasal administration |
| 01/15/2003 | EP1275724A1 Bonding reagents for cell surface protein and effector cells |
| 01/15/2003 | EP1275396A2 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 01/15/2003 | EP1275391A1 Pharmaceutical compositions containing irbesartan and a diuretic |
| 01/15/2003 | EP1275387A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process |
| 01/15/2003 | EP1275383A1 Modified release pharmaceutical composition containing Bupropion HCI as active substance |
| 01/15/2003 | EP1275382A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 01/15/2003 | EP1275378A2 Particulate construct comprising polyhydroxyalkanoate and method for producing it |
| 01/15/2003 | EP1275377A1 Granulates containing liposoluble substances and process of preparation thereof |
| 01/15/2003 | EP1275375A1 Aerosol compositions |
| 01/15/2003 | EP1275374A1 Buccal, non-polar spray or capsule comprising analgesics or alkaloids |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274750A1 Hydrophilic polymers, pressure sensitive adhesives and coatings |
| 01/15/2003 | EP1274728A2 Methods and compositions for the prevention and treatment of anemia |
| 01/15/2003 | EP1274723A2 ACTIVATION OF PEPTIDE PRODRUGS BY hK2 |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274473A2 Antimicrobial bioabsorbable materials |
| 01/15/2003 | EP1274462A2 Targeted transfection of cells using a biotinylated dendrimer |
| 01/15/2003 | EP1274461A2 Rhamm peptide conjugates |
| 01/15/2003 | EP1274459A2 Sustained release formulations comprising growth hormone |
| 01/15/2003 | EP1274443A1 Micelles |
| 01/15/2003 | EP1274441A1 Respiratory compositions |
| 01/15/2003 | EP1274440A1 Medical combinations comprising tiotropium and mometasone |
| 01/15/2003 | EP1274439A1 Medical combination comprising salmeterol and budesonide |
| 01/15/2003 | EP1274438A1 Medical combinations comprising tiotropium and budesonide |
| 01/15/2003 | EP1274437A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 01/15/2003 | EP1274436A1 Medical compositions comprising (r,r)-formoterol und rofleponide |
| 01/15/2003 | EP1274434A1 Medical combinations comprising tiotropium and rofleponide |
| 01/15/2003 | EP1274433A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| 01/15/2003 | EP1274432A1 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| 01/15/2003 | EP1274429A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 01/15/2003 | EP1274427A1 Formulation of substituted benzimidazoles |
| 01/15/2003 | EP1274425A1 Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
| 01/15/2003 | EP1274412A1 Pharmaceutical formulation |
| 01/15/2003 | EP1274406A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 01/15/2003 | EP1274405A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 01/15/2003 | EP1274404A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| 01/15/2003 | EP1274402A1 Pharmaceutical composition for the controlled release of paracetamol |
| 01/15/2003 | EP1274400A1 Physically stabilized dry powder formulations |
| 01/15/2003 | EP1274398A2 Effervescent granules and methods for their preparation |
| 01/15/2003 | EP1274397A2 Drug delivery composition and device |
| 01/15/2003 | EP1274321A1 Use of polyphosphate as a tooth erosion inhibitor in acidic compositions |
| 01/15/2003 | EP1274319A2 Compositions and methods for improving vascular health |
| 01/15/2003 | EP1163007B1 Propofol formulation containing tris |
| 01/15/2003 | EP1156788B1 Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| 01/15/2003 | EP1150643B1 Microemulsion containing alkano lammonium salts of fatty alcohol sulfates and/or alkylpoly alkylene glykol ether sulfates |
| 01/15/2003 | EP1112064B1 Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications |
| 01/15/2003 | EP1063998B1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/15/2003 | EP1009524B1 Improvements in or relating to capsules |
| 01/15/2003 | EP0991405B1 Clear, injectable formulation of an anesthetic compound |
| 01/15/2003 | EP0778767B1 Delivery of solid drug compositions |
| 01/15/2003 | EP0730444B1 Sustained release formulations for 24 hour release of metoprolol |
| 01/15/2003 | EP0701436B1 Process |
| 01/15/2003 | CN1391485A Particulate vitamin composition |
| 01/15/2003 | CN1391483A Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins |
| 01/15/2003 | CN1391478A Aqueous solution formulation of alpha-interferon |
| 01/15/2003 | CN1391476A Vasopressin agonist formulation and process |
| 01/15/2003 | CN1391472A Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 01/15/2003 | CN1391471A Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 01/15/2003 | CN1391467A Method of microencapsulation |
| 01/15/2003 | CN1391466A Vasopressin antagonist formulation and process |
| 01/15/2003 | CN1391465A 包衣 Coating |
| 01/15/2003 | CN1391463A Intranasal influenza virus vaccine |
| 01/15/2003 | CN1390878A Improved solid media |
| 01/15/2003 | CN1390605A Medicine C-AEDP using C as carrier for target therapy of osteopath and its usage |
| 01/15/2003 | CN1390582A Crude drugs pastes |
| 01/15/2003 | CN1098863C Photocured cross-linked-hyaluronic acid gel and method of preparation thereof and biomedical material |